Cardiovascular Outcomes: The SELECT Trial Revolution Breakthrough Cardiovascular Evidence The Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial represents a paradigm shift in obesity treatment by demonstrating cardiovascular benefits independent of diabetes status
Understanding Anthem and GLP-1 medications GLP-1 receptor agonists have transformed the weight loss landscape
If you miss a dose, inject it as soon as you remember, as long as it's at least 48 hours before your next scheduled dose
Preventing Disease Food safety, health, and nutrition news: Nov
Injectable GLP-1 agonists and meals For subcutaneous injectable formulations, including semaglutide, tirzepatide, dulaglutide, and liraglutide, there is no requirement to time your injection around meals
Semaglutide participants regained about two-thirds of their lost weight at 52 weeks, and a tirzepatide withdrawal trial also measured substantial regain